中国医药(600056.SH)：子公司药品通过仿制药一致性评价

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration for the supplemental application of Lincomycin Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved drug, Lincomycin Hydrochloride Injection, is primarily used to treat severe infections caused by sensitive strains such as Streptococcus, Pneumococcus, and Staphylococcus [1]